You read it here first. Three congressmen today wrote a letter to the House Energy and Commerce Committee to hold a hearing into allegations that undislosed financial conflicts of interest among FDA advisory committee members may have swayed an FDA decision to delay approval of Provenge, a prostate cancer vaccine being developed by Dendreon.
